Future oncology最新文献

Flavonol-mediated modulation of angiogenesis-related microRNAs in breast cancer: a narrative synthesis of current evidence and knowledge gaps. 黄酮醇介导的血管生成相关microrna在乳腺癌中的调节：当前证据和知识空白的叙述综合。

IF 2.6 4区医学

Future oncology Pub Date : 2026-05-08 DOI: 10.1080/14796694.2026.2665816

Dakalo Portia Ramali, Tania Mmapule Maphoso, Thanyani Victor Mulaudzi, Melvin Ambele, Vinesh Maharaj, Peace Mabeta, Botle Precious Damane

{"title":"Flavonol-mediated modulation of angiogenesis-related microRNAs in breast cancer: a narrative synthesis of current evidence and knowledge gaps.","authors":"Dakalo Portia Ramali, Tania Mmapule Maphoso, Thanyani Victor Mulaudzi, Melvin Ambele, Vinesh Maharaj, Peace Mabeta, Botle Precious Damane","doi":"10.1080/14796694.2026.2665816","DOIUrl":"https://doi.org/10.1080/14796694.2026.2665816","url":null,"abstract":"Angiogenesis is essential for breast cancer progression and metastasis; however, the clinical impact of vascular endothelial growth factor (VEGF)-targeted therapies remains limited due to adaptive resistance and activation of compensatory angiogenic pathways. Angiogenesis-regulating microRNAs (angiomiRs) act as upstream modulators of both VEGF-dependent and VEGF-independent signaling networks contributing to vascular plasticity, immune evasion, and therapeutic escape. Dietary flavonols such as kaempferol, myricetin, and quercetin have demonstrated anti-angiogenic activity in preclinical models, yet their mechanistic interaction with angiomiR-mediated regulation in breast cancer remains poorly characterized. This narrative review critically evaluates evidence identified through structured searches of Google Scholar, PubMed, Scopus, and Web of Science (2010-2026). We synthesize mechanistic and translational findings linking flavonols to microRNA-associated regulation of hypoxia signaling, endothelial activation, extracellular vesicle communication, and vascular normalization. Available evidence indicates that flavonols may influence angiogenic pathways both directly, by inhibiting key signaling cascades, and indirectly, through modulation of non-coding RNA networks. Despite these insights, experimental validation of specific flavonol-angiomiR interactions in breast cancer remains limited. AngiomiR modulation by flavonols, therefore, represents a mechanistically grounded but predominantly preclinical concept that warrants further translational investigation to clarify its therapeutic relevance and potential applications within precision oncology in breast cancer.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-21"},"PeriodicalIF":2.6,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The early changed rate of sTg to TSH ratio had superior predictive value in evaluating long-term prognosis for pulmonary metastatistic differentiated thyroid carcinoma. sTg / TSH比值的早期变化率对评价肺转移分化型甲状腺癌的远期预后有较好的预测价值。

IF 2.6 4区医学

Future oncology Pub Date : 2026-05-08 DOI: 10.1080/14796694.2026.2662500

Jiao Li, Yingying Zhang, Congcong Wang, Chenghui Lu, Na Han, Guoqiang Wang, Qiang Jia, Jian Tan, Xufu Wang, Zhaowei Meng

{"title":"The early changed rate of sTg to TSH ratio had superior predictive value in evaluating long-term prognosis for pulmonary metastatistic differentiated thyroid carcinoma.","authors":"Jiao Li, Yingying Zhang, Congcong Wang, Chenghui Lu, Na Han, Guoqiang Wang, Qiang Jia, Jian Tan, Xufu Wang, Zhaowei Meng","doi":"10.1080/14796694.2026.2662500","DOIUrl":"https://doi.org/10.1080/14796694.2026.2662500","url":null,"abstract":"Objective: This study aims to explore the predictive value of serological markers for the prognosis of pulmonary metastatic differentiated thyroid carcinoma (pmDTC).Materials and methods: This retrospective study enrolled 149 pmDTC patients who underwent thyroidectomy and radioactive iodine therapy (RAI). The patients were divided into disease control (DC) group and progressive disease (PD) group at the final follow-up. Univariate and multivariate logistic regression, receiver operating characteristic curves, and Kaplan‒Meier analysis were used to analyze the prognostic factors.Results: Age at diagnosis (OR = 1.116, 95% CI: 1.012-1.231; p = 0.028), primary tumor size (OR = 3.563, 95% CI: 1.173-10.821; p = 0.025), stimulated thyroglobulin (sTg) to thyrotrophin (TSH) ratio before the second RAI cycle (sTg/TSH2) (OR = 1.029, 95% CI: 1.001-1.058; p = 0.040), and the changed rate of TSH-adjusted sTg (ΔsTg/TSH) between the first two RAI cycles (adjusted OR = 23.078, 95% CI: 13.726-98.753; p = 0.031) were independent predictors of PD. ΔsTg/TSH demonstrated the highest predictive value for PD, with a sensitivity, specificity, negative predictive value, and accuracy of 100.0%, 88.4%, 100.0%, and 91.3%, respectively.Conclusion: ΔsTg/TSH demonstrates superior predictive value for PD in pmDTC, suggesting that serial monitoring of sTg and TSH enables earlier and more precise identification of pmDTC patients who would not derive clinical benefit from RAI.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-12"},"PeriodicalIF":2.6,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Highlights of the San Antonio Breast Cancer Symposium 2025 (Part 1). 2025年圣安东尼奥乳腺癌研讨会的亮点（第一部分）。

IF 2.6 4区医学

Future oncology Pub Date : 2026-05-05 DOI: 10.1080/14796694.2026.2668554

John R Benson, Ismail Jatoi

引用次数: 0

Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial. 在NAPOLI 3试验中，UGT1A1*28多态性对NALIRIFOX治疗的转移性胰腺导管腺癌患者的影响

IF 2.6 4区医学

Future oncology Pub Date : 2026-05-04 DOI: 10.1080/14796694.2026.2664776

Maen Abdelrahim, Gazala Khan, Hassan Hatoum, Alice Zervoudakis, Farshid Dayyani, Li Zhang, Jia Li, Fiona Maxwell, Eileen M O'Reilly, Zev A Wainberg, Andrea Bullock

{"title":"Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial.","authors":"Maen Abdelrahim, Gazala Khan, Hassan Hatoum, Alice Zervoudakis, Farshid Dayyani, Li Zhang, Jia Li, Fiona Maxwell, Eileen M O'Reilly, Zev A Wainberg, Andrea Bullock","doi":"10.1080/14796694.2026.2664776","DOIUrl":"https://doi.org/10.1080/14796694.2026.2664776","url":null,"abstract":"Aims: To evaluate the effect of UGT1A1*28 homozygosity on the safety profile of NALIRIFOX (liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in NAPOLI 3 (NCT04083235).Methods: This pre-specified exploratory analysis evaluated safety outcomes by UGT1A1*28 status in patients with mPDAC receiving NALIRIFOX or gemcitabine plus nab-paclitaxel in NAPOLI 3. All patients receiving NALIRIFOX initiated liposomal irinotecan at the full starting dose.Results: Among 749 treated patients, 83 were homozygous for UGT1A1*28. In the NALIRIFOX arm, grade ≥3 and serious treatment-emergent adverse events (TEAEs) related to liposomal irinotecan occurred in 61.5% and 33.3% of patients with homozygous UGT1A1*28 (n = 39), respectively, compared with 63.7% and 22.9% of patients with other genotypes (n = 328). The most common any-grade TEAEs for NALIRIFOX were diarrhea (59.0%), nausea (56.4%), vomiting (46.2%), and anemia (41.0%) in the homozygous group and diarrhea (71.6%), nausea (59.8%), vomiting (38.4%), and decreased appetite (38.1%) in the other genotypes group. Rates of TEAE-related treatment discontinuation and dose reduction/interruption in the NALIRIFOX arm were similar across genotypes.Conclusions: UGT1A1*28 homozygosity was not associated with increased toxicity in patients receiving NALIRIFOX in NAPOLI 3. These findings support the use of full NALIRIFOX dosing irrespective of UGT1A1*28 status.Clinical trial registration: www.clinicaltrials.gov identifier is NCT04083235; EudraCT 2018-003585-14.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-8"},"PeriodicalIF":2.6,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147814101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world clinical outcomes in patients with biochemical recurrence after local therapy for non-metastatic prostate cancer. 非转移性前列腺癌局部治疗后生化复发患者的实际临床结果。

IF 2.6 4区医学

Future oncology Pub Date : 2026-05-01 Epub Date: 2026-04-29 DOI: 10.1080/14796694.2026.2661772

Neal D Shore, Nasreen Khan, Rana R McKay, Niculae Constantinovici, Guifang Chen, Vlasta Hlebec, Shankar Srinivasan, Zdravko Vassilev, Daniel E Spratt

{"title":"Real-world clinical outcomes in patients with biochemical recurrence after local therapy for non-metastatic prostate cancer.","authors":"Neal D Shore, Nasreen Khan, Rana R McKay, Niculae Constantinovici, Guifang Chen, Vlasta Hlebec, Shankar Srinivasan, Zdravko Vassilev, Daniel E Spratt","doi":"10.1080/14796694.2026.2661772","DOIUrl":"10.1080/14796694.2026.2661772","url":null,"abstract":"Aims: We assessed the proportion of patients with biochemical recurrence (BCR), the occurrence of BCR in risk groups according to prostate-specific antigen doubling time (PSA-DT), and clinical outcomes in risk groups.Patients and methods: Retrospective observational study of patients with non-metastatic prostate cancer (PC) (n = 26,755) in the US using the Optum® PC electronic medical record database. Primary outcomes were the proportion of patients with BCR in prior radical prostatectomy (RP) or radiation therapy (RT) cohorts. Secondary outcomes included association between baseline characteristics and time to BCR, BCR risk group (high-risk: PSA-DT <12 months; low-risk: PSA-DT ≥12 months), and time from BCR to metastasis and castration-resistant PC (CRPC).Results: BCR occurred in 19.7% of patients after RP and 8.8% after RT. Among high-risk BCR patients (n = 523) in the RP cohort, 19.3% developed metastasis, 14.5% developed CRPC, and 14.1% died. In contrast, among low-risk BCR patients (n = 1,356), rates were 10.2%, 7.0%, and 6.6%, respectively. In the RT cohort, 25.9% of the high-risk BCR patients (n = 498) developed metastasis, 21.5% developed CRPC, and 19.7% died, compared with 16.4%, 9.0%, and 16.4% among low-risk patients (n = 122), respectively.Conclusions: PSA and PSA-DT are key predictors of BCR. Outcomes are worse among high-risk BCR patients with short PSA-DT.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1311-1319"},"PeriodicalIF":2.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147769581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world treatment patterns and outcomes of patients with multiple myeloma initiating elranatamab: results from the ALTITUDE-1 and ALTITUDE-2 retrospective cohort studies. 使用elranatamab治疗多发性骨髓瘤患者的现实世界治疗模式和结果：来自ALTITUDE-1和ALTITUDE-2回顾性队列研究的结果

IF 2.6 4区医学

Future oncology Pub Date : 2026-05-01 Epub Date: 2026-04-23 DOI: 10.1080/14796694.2026.2662504

Rahul Banerjee, Meera Mohan, Bhavesh Shah, Patricia Prince, Nileesa Gautam, Elisha Beebe, William Pajerowski, Cera Cantu, Hannah Meiseles, David Hughes, Guido Nador, Rickard Sandin, Patrick Hlavacek, Benjamin Li, Aster Meche, Chai Hyun Kim, Isabel Perez Cruz, Mohsena Sumaya, Marco DiBonaventura

{"title":"Real-world treatment patterns and outcomes of patients with multiple myeloma initiating elranatamab: results from the ALTITUDE-1 and ALTITUDE-2 retrospective cohort studies.","authors":"Rahul Banerjee, Meera Mohan, Bhavesh Shah, Patricia Prince, Nileesa Gautam, Elisha Beebe, William Pajerowski, Cera Cantu, Hannah Meiseles, David Hughes, Guido Nador, Rickard Sandin, Patrick Hlavacek, Benjamin Li, Aster Meche, Chai Hyun Kim, Isabel Perez Cruz, Mohsena Sumaya, Marco DiBonaventura","doi":"10.1080/14796694.2026.2662504","DOIUrl":"10.1080/14796694.2026.2662504","url":null,"abstract":"Background and aim: Elranatamab is a bispecific antibody currently approved in the United States (US) for the treatment of relapsed/refractory multiple myeloma (MM). Given its recent approval, real-world data are limited.Methods: Results from two real-world (RW) studies using administrative claims (ALTITUDE-1) and fee-for-service data (ALTITUDE-2) are collectively reported here. US patients with MM who initiated elranatamab after August 2023 were included and followed through September/October 2025. Patient characteristics, clinical history, treatment patterns, and effectiveness outcomes were reported.Results: One hundred and eighty-three and 391 patients were included from ALTITUDE-1 and -2, respectively. Median ages were 73 and 75, 43.2% and 33.0% were penta-drug exposed, and 17.5% and 21.0% were previously BCMA-exposed, respectively. RW treatment patterns showed less frequent dosing (27.9 and 27.1 elranatamab vials used per year) compared with expected on-label dosing (39 vials per year). Neither median time-to-next-treatment or death or median overall survival were reached; landmark analyses for each study estimated 70.0% (ALTITUDE-1) and 60.7% (ALTITUDE-2) of patients alive at 18 months.Conclusion: US patients treated with elranatamab in the RW setting were heavily pre-treated. RW treatment patterns suggest less frequent administration of elranatamab compared with the label and effectiveness consistent with clinical trial results (MagnetisMM-3 trial [NCT04649359]).","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1331-1340"},"PeriodicalIF":2.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147769590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systemic immune-inflammation index may be used to predict the development of colorectal cancer from colonic polyps. 系统免疫炎症指数可用于预测结肠息肉的发展。

IF 2.6 4区医学

Future oncology Pub Date : 2026-05-01 Epub Date: 2026-03-19 DOI: 10.1080/14796694.2025.2609975

Ying Chun, Jing Xia, Chaosheng Peng

{"title":"Systemic immune-inflammation index may be used to predict the development of colorectal cancer from colonic polyps.","authors":"Ying Chun, Jing Xia, Chaosheng Peng","doi":"10.1080/14796694.2025.2609975","DOIUrl":"10.1080/14796694.2025.2609975","url":null,"abstract":"Aims: This study aims to assess whether the Systemic Immune-Inflammation Index (SII) can serve as a predictive biomarker for the progression of colonic polyps to colorectal cancer (CRC).Patients & methods: A total of 351 individuals (236 with colonic polyps and 115 with CRC) who underwent colonoscopy and received a pathological diagnosis at The Six Medical Center of PLA General Hospital were included. Demographic, clinical, and laboratory data were collected. SII was calculated using neutrophil, monocyte, and lymphocyte counts. Statistical analyses, including univariate and multivariate logistic regression, identified risk factors for CRC development, and receiver operating characteristic (ROC) curves were used to assess the diagnostic performance of SII and CEA.Results: SII was significantly higher in CRC patients compared to those with colonic polyps (P < 0.001). Univariate and multivariate analyses revealed that SII, CEA, and lymphocyte count were independent predictors of CRC. ROC analysis showed that SII had a good diagnostic performance with an AUC of 0.823, sensitivity of 80.9%, and specificity of 72.0%.Conclusions: SII is a promising, noninvasive biomarker for identifying patients at increased risk of CRC among those with colonic polyps. Further prospective studies are needed to confirm these findings.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1321-1329"},"PeriodicalIF":2.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147485387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Protocol for a pilot-randomized trial in newly diagnosed glioblastoma: standard care with or without daily intranasal perillyl alcohol. 新诊断的胶质母细胞瘤的试点随机试验方案：每日鼻内紫苏醇或不使用紫苏醇的标准治疗

IF 2.6 4区医学

Future oncology Pub Date : 2026-05-01 Epub Date: 2026-04-22 DOI: 10.1080/14796694.2026.2652540

Daniela Carneiro de Lima, Axel H Schönthal, Clóvis Orlando Pereira da Fonseca, Fabiano Reis, Carmen Silvia Passos Lima, Mary Ann Foglio

{"title":"Protocol for a pilot-randomized trial in newly diagnosed glioblastoma: standard care with or without daily intranasal perillyl alcohol.","authors":"Daniela Carneiro de Lima, Axel H Schönthal, Clóvis Orlando Pereira da Fonseca, Fabiano Reis, Carmen Silvia Passos Lima, Mary Ann Foglio","doi":"10.1080/14796694.2026.2652540","DOIUrl":"10.1080/14796694.2026.2652540","url":null,"abstract":"Glioblastoma (GB) is a highly malignant brain tumor with poor prognosis and limited treatment options. Standard treatment, surgery followed by chemoradiation with temozolomide (TMZ), yields an average survival of 18 months. Preclinical studies indicate that perillyl alcohol (POH) is cytotoxic to TMZ-sensitive and -resistant cells and acts as a radiosensitizer. Clinical studies of intranasal POH show low toxicity and potential survival benefits in recurrent gliomas. This study aims to evaluate the effects of POH alongside standard treatment in newly diagnosed GB patients. Eligible patients at the Oncology Services of the University of Campinas General Hospital and Municipal Hospital Mário Gatti will be assigned to a control group (chemoradiation) or an intervention group (chemoradiation + POH). Follow-up will occur every 4 months for 1 year. The primary outcome is progression-free survival, with secondary outcomes including overall survival, blood levels of P-selectin and von Willebrand factor, and tumor response assessed by cranial MRI. Previous studies have reported positive effects of intranasal POH in patients with recurrent gliomas. This study evaluates an adjunct protocol combining intranasal POH with standard therapy in newly diagnosed GB patients. This randomized clinical trial aims to support future research and guide clinical practice.Clinical trial registration: RBR-4ngc9n5 (www.ensaiosclinicos.gov.br).","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1263-1271"},"PeriodicalIF":2.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147769588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mitomycin for intravesical treatment of low-grade intermediate-risk non-muscle invasive bladder cancer. 丝裂霉素膀胱内治疗低级别、中危非肌性浸润性膀胱癌。

IF 2.6 4区医学

Future oncology Pub Date : 2026-05-01 Epub Date: 2026-04-27 DOI: 10.1080/14796694.2026.2661768

Ludovica Cella, Alessio Finocchiaro, Aleksander Ślusarczyk, Wojciech Krajewski, Jorge Caño Velasco, José Daniel Subiela, Francesco Claps, Elisabeth Grobet-Jeandin, Francesco Del Giudice, Andrea Gallioli, Ekaterina Laukhtina, Gautier Marcq, Andrea Mari, Luca Afferi, Simone Albisinni, Francesco Soria, Rodolfo Hurle, Marco Paciotti, Matteo Ferro, Sisto Perdonà, Laura S Mertens, Marco Moschini, Benjamin Pradere, Roberto Contieri

{"title":"Mitomycin for intravesical treatment of low-grade intermediate-risk non-muscle invasive bladder cancer.","authors":"Ludovica Cella, Alessio Finocchiaro, Aleksander Ślusarczyk, Wojciech Krajewski, Jorge Caño Velasco, José Daniel Subiela, Francesco Claps, Elisabeth Grobet-Jeandin, Francesco Del Giudice, Andrea Gallioli, Ekaterina Laukhtina, Gautier Marcq, Andrea Mari, Luca Afferi, Simone Albisinni, Francesco Soria, Rodolfo Hurle, Marco Paciotti, Matteo Ferro, Sisto Perdonà, Laura S Mertens, Marco Moschini, Benjamin Pradere, Roberto Contieri","doi":"10.1080/14796694.2026.2661768","DOIUrl":"10.1080/14796694.2026.2661768","url":null,"abstract":"Intravesical mitomycin C (MMC) is a cornerstone therapy for non-muscle-invasive bladder cancer (NMIBC), effectively reducing recurrence in low-grade intermediate-risk patients. We conducted a narrative synthesis of randomized and prospective studies evaluating intravesical MMC across three clinical settings: single immediate post-transurethral resection of bladder tumor (TURBT) instillation, adjuvant multiple instillations, and chemoablation in low- and intermediate-risk NMIBC. Single immediate instillation after uncomplicated TURBT effectively reduces early recurrences in low-risk NMIBC. In intermediate-risk patients, available evidence indicates that adjuvant MMC reduces recurrence by 30-50% versus TURBT alone, with recurrence-free survival gains of 20-35% and minimal systemic toxicity; maintenance cycles further enhance durability when consistently administered. Device-assisted strategies, may further improve recurrence control. For selected patients, MMC-based chemoablation offers a non-surgical outpatient option with encouraging tumor response rates. MMC offers a favorable balance of oncologic efficacy, safety, and logistical feasibility. Evidence supports routine post-TURBT use in low-risk disease, adjuvant benefit in intermediate-risk patients, and emerging chemoablation for selected recurrences, reinforcing MMC as a reliable, accessible component of modern NMIBC management.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1291-1299"},"PeriodicalIF":2.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147769553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phase II basket study of brigatinib for ALK fusion-positive solid tumors: WJOG15221M/ALLBREAK (a decentralized clinical trial design). 布加替尼治疗ALK融合阳性实体瘤的II期篮子研究：WJOG15221M/ALLBREAK（分散式临床试验设计）。

IF 2.6 4区医学

Future oncology Pub Date : 2026-05-01 Epub Date: 2026-04-15 DOI: 10.1080/14796694.2026.2658642

Tomoki Sakakida, Toshiki Masuishi, Takuma Onoe, Keigo Komine, Kan Yonemori, Takao Fujisawa, Kazuaki Harada, Satoshi Hamauchi, Kentaro Tokumo, Taito Esaki, Yukihiko Hiroshima, Satomi Watanabe, Masako Asayama, Waki Hosoda, Hiroya Taniguchi, Hidetoshi Hayashi, Kei Muro

{"title":"Phase II basket study of brigatinib for ALK fusion-positive solid tumors: WJOG15221M/ALLBREAK (a decentralized clinical trial design).","authors":"Tomoki Sakakida, Toshiki Masuishi, Takuma Onoe, Keigo Komine, Kan Yonemori, Takao Fujisawa, Kazuaki Harada, Satoshi Hamauchi, Kentaro Tokumo, Taito Esaki, Yukihiko Hiroshima, Satomi Watanabe, Masako Asayama, Waki Hosoda, Hiroya Taniguchi, Hidetoshi Hayashi, Kei Muro","doi":"10.1080/14796694.2026.2658642","DOIUrl":"10.1080/14796694.2026.2658642","url":null,"abstract":"Anaplastic lymphoma kinase (ALK) rearrangements, oncogenic drivers found in 3-5% of non-small cell lung cancer (NSCLC), are also detected in 0.2% of other solid tumors with poor prognosis. Brigatinib, a second-generation ALK-tyrosine kinase inhibitor (ALK-TKI), has shown potential efficacy in ALK fusion-positive tumors besides NSCLC, supported by preclinical studies and case reports. The WJOG15221M/ALLBREAK trial was designed to evaluate the safety and efficacy of brigatinib in these rare cancers.This multicenter, open-label, single-arm, phase II basket trial enrolls patients with advanced or recurrent ALK fusion-positive solid tumors who are refractory to or intolerant of standard therapies. By adopting a decentralized clinical trial (DCT) platform, the study allows patients to participate either through on-site visits or video conferencing systems at their nearby hospitals, thereby enhancing accessibility and inclusivity, while facilitating enrollment from diverse locations. ALK fusion genes are identified by next-generation sequencing (NGS) or by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Due to rapid enrollment, the target sample size was expanded to 28 patients. The primary endpoint is objective response rate confirmed by central assessment; secondary endpoints include duration of response, progression-free survival, overall survival, and safety.Clinical trial registration: jRCT2041210148 (https://jrct.mhlw.go.jp).","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1273-1279"},"PeriodicalIF":2.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147689521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0